Swiss National Bank Boosts Holdings in OPKO Health by 15.7%
June 4, 2023
☀️Trending News
On the 14th of April, the Swiss National Bank (SNB) made a noteworthy move and increased its holdings in OPKO ($NASDAQ:OPK) Health Inc. by 15.7%. OPKO Health Inc. is a publicly traded biopharmaceutical and diagnostics company headquartered in Miami, Florida. The company specializes in delivering innovative and reliable healthcare products and services worldwide to improve the health and well-being of patients. Through its subsidiaries, OPKO operates comprehensive medical and diagnostic laboratories, a pharmaceutical manufacturing and development business, a robust clinical research organization, and multiple retail pharmacy franchises. The strong performance of OPKO is likely to attract further institutional investors and bolster confidence in the stock.
Analysis
We at GoodWhale have conducted an extensive analysis of OPKO HEALTH‘s financial and business wellbeing. Based on our Risk Rating, we have deemed OPKO HEALTH to be a medium risk investment. We have detected two risk warnings in the income sheet and balance sheet of OPKO HEALTH. If you are interested in understanding more, please register on GoodWhale.com and take a look at our detailed report. Through our report, we will help you understand the risk profile of OPKO HEALTH and enable you to make an informed decision when it comes to investing in the company. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Opko Health. More…
| Total Revenues | Net Income | Net Margin |
| 912.58 | -291.27 | -33.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Opko Health. More…
| Operations | Investing | Financing |
| -95.19 | 91.04 | 22.97 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Opko Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.17k | 617.8 | 2.02 |
Key Ratios Snapshot
Some of the financial key ratios for Opko Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.8% | – | -36.8% |
| FCF Margin | ROE | ROA |
| -13.1% | -13.4% | -9.7% |
Peers
The company operates through four segments: Diagnostics, Biopharmaceuticals, Pharmaceuticals, and Corporate. The Diagnostics segment offers tests and products for the detection of disease markers, such as PSA tests for the detection of prostate cancer, genetic tests, and tests for the detection of infectious diseases. The Biopharmaceuticals segment focuses on the development and commercialization of biologics products, such as human growth hormone therapy, gene therapy, and vaccines. The Pharmaceuticals segment focuses on the development and commercialization of small molecule drugs. The Corporate segment represents the general and administrative expenses of the company.
– Psychemedics Corp ($NASDAQ:PMD)
Psychemedics Corporation is a biotechnology company that develops and markets products and services for the detection of drugs of abuse through the analysis of hair samples. The company was founded in 1987 and is headquartered in Canton, Massachusetts.
– IDenta Corp ($OTCPK:IDTA)
Denta Corp is a dental products company with a market cap of 1.42M as of 2022. The company has a Return on Equity of -10.42%. The company manufactures and sells dental products such as toothpaste, toothbrushes, floss, and mouthwash. The company also provides dental services such as teeth whitening and cleaning.
– Eurofins Scientific SE ($LTS:0MV5)
Eurofins Scientific SE is a world leader in food, environmental, pharmaceutical and cosmetics products testing. It has a market cap of 12.5B as of 2022 and a return on equity of 12.32%. The company provides an extensive range of testing services to ensure the safety and quality of food, pharmaceutical and cosmetics products. It also offers environmental testing services to monitor and protect the environment from pollution.
Summary
Investors are paying attention to OPKO Health Inc. after the Swiss National Bank increased its holdings in the company by an impressive 15.7% on April 14th. With this move, analysts are expecting the company’s stock to continue to rise, as investors look for potential returns from their investments in OPKO. Analysts are also keeping a close eye on the company’s financial performance and developments in its core businesses, such as diagnostic services and pharmaceuticals.
They are also keeping an eye on the company’s ability to develop new technologies, such as its long-term collaboration with Pfizer for cancer therapeutics. Investors will also be looking at OPKO’s ability to create new partnerships with other healthcare companies, which could provide further opportunities for growth.
Related Posts
Recent Posts
